JENNIFER NERF: Open Payments
NPI 1790020741 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,782 in 60 payments from 11 companies in 2025. Trend: 2023 $353 · 2024 $1,052 · 2025 $1,782
Food & beverage: $1,782
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 15 | $504 |
| Ipsen Biopharmaceuticals, Inc | 12 | $327 |
| Gilead Sciences, Inc. | 13 | $255 |
| Mirum Pharmaceuticals, Inc. | 3 | $138 |
| Janssen Biotech, Inc. | 1 | $129 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $120 |
| Mallinckrodt Hospital Products Inc. | 4 | $113 |
| Janssen Scientific Affairs, LLC | 1 | $65 |
| Novo Nordisk Inc | 2 | $61 |
| Intercept Pharmaceuticals, Inc. | 2 | $45 |
Products named: REZDIFFRA, IQIRVO, TREMFYA, Livmarli, XIFAXAN, TERLIVAZ, Wegovy, OCALIVA.
Industry payments across MD — which companies pay providers there.
